Khalid Abdalla1, Shaker Abdullah2, Abeer Almehdar2, Naglla Elimam2, Mohammed Burhan Abrar2, Wasil Jastaniah2,3. 1. Princess Noorah Oncology Center, King Saud Bin Abdulaziz University and King Abdulaziz Medical City, P.O.BOX 9515, Jeddah, 21423, Saudi Arabia. ps.remed@gmail.com. 2. Princess Noorah Oncology Center, King Saud Bin Abdulaziz University and King Abdulaziz Medical City, P.O.BOX 9515, Jeddah, 21423, Saudi Arabia. 3. Department of Pediatrics, College of Medicine, Umm AlQura University, Makkah, Saudi Arabia.
Abstract
BACKGROUND: Treatment modality impacts outcome of childhood low-grade glioma (LGG). Optimizing management in developing countries can be challenging. This study evaluates the clinical characteristics, treatment, and factors influencing outcome of childhood LGG in Saudi Arabia. PATIENTS AND METHODS: This study retrospectively evaluated 59 children consecutively diagnosed with LGG between January 2001 and June 2016. RESULTS: Median age at diagnosis was 6.0 years. Pilocytic astrocytoma represented 64.9% of cases. The anatomic site was cerebellar in 23.7%, cerebral in 18.6%, hypothalamic-optic pathway in 33.9%, and midline in 23.7%. The 5-year overall survival (OS) and progression-free survival (PFS) were 90.6 ± 4.7 and 54.3 ± 8.4%, respectively. Initial treatment was observation in 28.8%, surgery alone in 35.6%, chemotherapy in 13.6%, radiotherapy in 5.1%, and combined in 16.9% of cases. The corresponding 5-year PFS was 56.3 ± 15.6, 53.3 ± 14.0, 22.9 ± 19.7, 33.3 ± 27.2, and 88.9 ± 10.5%, respectively (p = 0.006). Among the 61% who had surgical intervention (either alone or in combination with other therapies), 22% achieved complete resection with 5-year radiation/progression-free survival (RPFS) of 87.5 ± 11.7% compared to 27.6 ± 10.8% for subtotal resection/biopsy and 62.2 ± 17.0% for no surgery (p = 0.013). Adjuvant therapy for residual tumor improved survival with 5-year PFS of 66.7 ± 19.2% for chemotherapy and 100% for radiotherapy compared to 12.5 ± 11.4% for observation (p = 0.033). CONCLUSIONS: We identified variability in the outcomes of LGG. Fewer surgeries with lower rates of total resection were noted, compared to reports from international cooperative groups. The extent of resection was predictive of RPFS. Adjuvant therapy improved the outcome of patients with residual disease, resulting in PFS rates comparable to international data.
BACKGROUND: Treatment modality impacts outcome of childhood low-grade glioma (LGG). Optimizing management in developing countries can be challenging. This study evaluates the clinical characteristics, treatment, and factors influencing outcome of childhood LGG in Saudi Arabia. PATIENTS AND METHODS: This study retrospectively evaluated 59 children consecutively diagnosed with LGG between January 2001 and June 2016. RESULTS: Median age at diagnosis was 6.0 years. Pilocytic astrocytoma represented 64.9% of cases. The anatomic site was cerebellar in 23.7%, cerebral in 18.6%, hypothalamic-optic pathway in 33.9%, and midline in 23.7%. The 5-year overall survival (OS) and progression-free survival (PFS) were 90.6 ± 4.7 and 54.3 ± 8.4%, respectively. Initial treatment was observation in 28.8%, surgery alone in 35.6%, chemotherapy in 13.6%, radiotherapy in 5.1%, and combined in 16.9% of cases. The corresponding 5-year PFS was 56.3 ± 15.6, 53.3 ± 14.0, 22.9 ± 19.7, 33.3 ± 27.2, and 88.9 ± 10.5%, respectively (p = 0.006). Among the 61% who had surgical intervention (either alone or in combination with other therapies), 22% achieved complete resection with 5-year radiation/progression-free survival (RPFS) of 87.5 ± 11.7% compared to 27.6 ± 10.8% for subtotal resection/biopsy and 62.2 ± 17.0% for no surgery (p = 0.013). Adjuvant therapy for residual tumor improved survival with 5-year PFS of 66.7 ± 19.2% for chemotherapy and 100% for radiotherapy compared to 12.5 ± 11.4% for observation (p = 0.033). CONCLUSIONS: We identified variability in the outcomes of LGG. Fewer surgeries with lower rates of total resection were noted, compared to reports from international cooperative groups. The extent of resection was predictive of RPFS. Adjuvant therapy improved the outcome of patients with residual disease, resulting in PFS rates comparable to international data.
Entities:
Keywords:
Children; Developing countries; LGG; Outcome; Surgery
Authors: Tore Stokland; Jo-Fen Liu; James W Ironside; David W Ellison; Roger Taylor; Kathryn J Robinson; Susan V Picton; David A Walker Journal: Neuro Oncol Date: 2010-09-22 Impact factor: 12.300
Authors: Katrin Scheinemann; Ute Bartels; Elena Tsangaris; Cynthia Hawkins; Annie Huang; Peter Dirks; Iris Fried; Eric Bouffet; Uri Tabori Journal: Pediatr Blood Cancer Date: 2010-12-01 Impact factor: 3.167
Authors: Alvaro Lassaletta; Katrin Scheinemann; Shayna M Zelcer; Juliette Hukin; Beverley A Wilson; Nada Jabado; Anne Sophie Carret; Lucie Lafay-Cousin; Valerie Larouche; Cynthia E Hawkins; Gregory Russell Pond; Ken Poskitt; Daniel Keene; Donna L Johnston; David D Eisenstat; Rahul Krishnatry; Matthew Mistry; Anthony Arnoldo; Vijay Ramaswamy; Annie Huang; Ute Bartels; Uri Tabori; Eric Bouffet Journal: J Clin Oncol Date: 2016-10-10 Impact factor: 44.544
Authors: Rolf-Dieter Kortmann; Beate Timmermann; Roger E Taylor; Giovanni Scarzello; Ludwig Plasswilm; Frank Paulsen; Branislav Jeremic; Astrid K Gnekow; Karin Dieckmann; Sylvia Kay; Michael Bamberg Journal: Strahlenther Onkol Date: 2003-08 Impact factor: 3.621
Authors: Stephanie Puget; Darach W Crimmins; Matthew R Garnett; Jacques Grill; Ricardo Oliveira; Nathalie Boddaert; Alison Wray; Arielle Lelouch-Tubiana; Thomas Roujeau; Federico Di Rocco; Michel Zerah; Christian Sainte-Rose Journal: J Neurosurg Date: 2007-05 Impact factor: 5.115
Authors: Christoph Burkhard; Pier-Luigi Di Patre; Danielle Schüler; Georges Schüler; M Gazi Yaşargil; Yasuhiro Yonekawa; Urs M Lütolf; Paul Kleihues; Hiroko Ohgaki Journal: J Neurosurg Date: 2003-06 Impact factor: 5.115
Authors: V Doireau; J Grill; M Zerah; A Lellouch-Tubiana; D Couanet; P Chastagner; J C Marchal; Y Grignon; Z Chouffai; C Kalifa Journal: Br J Cancer Date: 1999-11 Impact factor: 7.640
Authors: Pratiti Bandopadhayay; Guillaume Bergthold; Wendy B London; Liliana C Goumnerova; Andres Morales La Madrid; Karen J Marcus; Dongjing Guo; Nicole J Ullrich; Nathan J Robison; Susan N Chi; Rameen Beroukhim; Mark W Kieran; Peter E Manley Journal: Pediatr Blood Cancer Date: 2014-01-30 Impact factor: 3.167